RxDoctor Payments Data

Hillary Lungren, DO

Family Medicine · Clearwater, FLNPI 1114283058

Payments from drug & device makers

$1,322in general payments, 2019–2025

Across 64 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$224
  • Merck$219
  • Novartis$177
  • AstraZeneca$164
  • GSK$131
  • Exact Sciences$121
  • plus $285 from 8 others

What the payments were for

  • Food & beverage$1,322100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,322 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$770
Medicare patients
41
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$46,231
TrulicityDulaglutide20$41,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$41,695
JardianceEmpagliflozin31$36,799
EliquisApixaban16$21,238
LantusInsulin Glargine,hum.Rec.Anlog11$6,595
Albuterol Sulfate HfaAlbuterol Sulfate85$3,504
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,792
Gabapentin71$2,730
Celecoxib22$1,742
Rosuvastatin Calcium48$1,634
Ventolin HfaAlbuterol Sulfate29$1,553
Atorvastatin Calcium190$1,321
Duloxetine Hcl37$971
Wixela InhubFluticasone Propion/Salmeterol17$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$46,23130 claims
Lilly USA, LLCTrulicity$18$41,80020 claims
GSKTrelegy Ellipta$131$41,69553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →